Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Organon ( (OGN) ) is now available.
On May 27, 2025, Organon & Co. announced that the U.S. Food and Drug Administration (FDA) granted interchangeability designation to their product HADLIMA™ (adalimumab-bwwd) as a biosimilar to Humira®. This designation allows pharmacists to substitute HADLIMA for Humira without consulting prescribers, potentially increasing patient access and reducing costs. The designation is based on studies demonstrating comparable pharmacokinetics, efficacy, safety, and immunogenicity with Humira. Organon emphasizes that this approval could lead to significant savings for patients and the healthcare system.
The most recent analyst rating on (OGN) stock is a Sell with a $20.00 price target. To see the full list of analyst forecasts on Organon stock, see the OGN Stock Forecast page.
Spark’s Take on OGN Stock
According to Spark, TipRanks’ AI Analyst, OGN is a Neutral.
Organon’s stock score reflects a challenging environment with declining revenues and high leverage, balanced by strong profitability margins and an attractive valuation. While technical indicators show bearish momentum, the stock’s low P/E ratio and high dividend yield suggest potential for upside. Recent corporate events and earnings call details indicate mixed sentiment, with growth in key segments but also significant financial challenges.
To see Spark’s full report on OGN stock, click here.
More about Organon
Average Trading Volume: 5,739,071
Technical Sentiment Signal: Sell
Current Market Cap: $2.26B
Find detailed analytics on OGN stock on TipRanks’ Stock Analysis page.